Raj Dominic S C, Shah Vallabh O, Rambod Mehdi, Kovesdy Csaba P, Kalantar-Zadeh Kamyar
George Washington University School of Medicine, North Washington, DC, USA.
Am J Kidney Dis. 2009 Dec;54(6):1062-71. doi: 10.1053/j.ajkd.2009.06.028. Epub 2009 Aug 20.
CD14 is a key molecule in innate immunity that mediates cell activation and signaling in response to endotoxin and other bacterial wall-derived components. CD14 protein exists in soluble (sCD14) and membrane-bound forms. The correlates of sCD14 in persons undergoing long-term hemodialysis (HD) therapy are not known. We hypothesized that increased sCD14 levels in HD patients are associated with proinflammatory cytokine activation and increased mortality.
Cohort study.
SETTING & PARTICIPANTS: 310 long-term HD patients who participated in the Nutritional and Inflammatory Evaluation in Dialysis (NIED) Study, a cohort derived from a pool of more than 3,000 HD outpatients during 5 years in 8 DaVita maintenance dialysis facilities in the South Bay Los Angeles, CA, area.
sCD14 levels in serum.
33-month mortality.
Mean sCD14 level was 7.24 +/- 2.45 microg/mL. Tumor necrosis factor alpha level was the strongest correlate of sCD14 level (r = +0.24; P < 0.001), followed by interleukin 6 level (r = +0.18; P = 0.002), serum ferritin level (r = +0.21; P < 0.001), total iron-binding capacity (r = -0.19; P < 0.001), body mass index (r = -0.15; P = 0.008), vintage (r = +0.14; P = 0.01), low-density lipoprotein cholesterol level (r = +0.13; P = 0.03), and body fat (r = -0.11; P = 0.06). During the 33-month follow-up, 71 (23%) patients died. Multivariable Cox proportional analysis adjusted for case-mix and other nutritional and inflammatory confounders, including serum tumor necrosis factor alpha, C-reactive protein, and interleukin 6 levels, showed that compared with the lowest sCD14 tertile, sCD14 levels in the third tertile (>7.8 microg/mL) were associated with greater death risk (hazard ratio, 1.94; 95% confidence interval, 1.01 to 3.75; P = 0.04).
Survivor bias in combined incident/prevalent studies.
Increased sCD14 level is related positively to markers of inflammation and negatively to nutritional status and is an independent predictor of mortality in long-term HD patients. Additional studies are needed to examine the usefulness of sCD14 level in risk stratification and the clinical decision-making process in HD patients.
CD14是天然免疫中的关键分子,可介导细胞对内毒素及其他细菌壁衍生成分的激活和信号传导。CD14蛋白以可溶性(sCD14)和膜结合形式存在。长期血液透析(HD)治疗患者中sCD14的相关因素尚不清楚。我们推测HD患者sCD14水平升高与促炎细胞因子激活及死亡率增加有关。
队列研究。
310例长期HD患者参与了透析营养与炎症评估(NIED)研究,该队列来自加利福尼亚州洛杉矶南湾地区8家达维塔维持性透析机构5年期间的3000多名HD门诊患者。
血清sCD14水平。
33个月死亡率。
sCD14平均水平为7.24±2.45微克/毫升。肿瘤坏死因子α水平是与sCD14水平相关性最强的因素(r = +0.24;P < 0.001),其次是白细胞介素6水平(r = +0.18;P = 0.002)、血清铁蛋白水平(r = +0.21;P < 0.001)、总铁结合力(r = -0.19;P < 0.001)、体重指数(r = -0.15;P = 0.008)、透析时间(r = +0.14;P = 0.01)、低密度脂蛋白胆固醇水平(r = +0.13;P = 0.03)和体脂(r = -0.11;P = 0.06)。在33个月的随访期间,71例(23%)患者死亡。多变量Cox比例分析对病例组合及其他营养和炎症混杂因素进行了校正,包括血清肿瘤坏死因子α、C反应蛋白和白细胞介素6水平,结果显示,与sCD14最低三分位数相比,第三三分位数(>7.8微克/毫升)的sCD14水平与更高的死亡风险相关(风险比,1.94;95%置信区间,1.01至3.75;P = 0.04)。
合并发病率/患病率研究中的幸存者偏倚。
sCD14水平升高与炎症标志物呈正相关,与营养状况呈负相关,是长期HD患者死亡率的独立预测因素。需要进一步研究以检验sCD14水平在HD患者风险分层和临床决策过程中的实用性。